Resolvyx to Present Data on Novel Resolvin Drug Candidates for Eye Disease at ARVO Annual MeetingBEDFORD, Mass.--(BUSINESS WIRE)--Apr 24, 2008 - Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that new preclinical data on its resolvin drug candidates will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida, being held April 27 to May 1, 2008.
"With a total of eight oral and poster presentations, we are delighted to have such a strong presence at ARVO, which is the premier global ocular meeting," said Per Gjorstrup, Ph.D., M.D., Co-Founder and Chief Medical Officer of Resolvyx. "Due to their unique mechanism of action in resolving inflammation and protecting healthy eye tissue, we have studied resolvins in multiple ocular indications, including retinal and dry eye diseases."
The schedule and meeting place for the sessions, together with the abstract information, are listed below: -0-
Oral/Paper Presentations: Date & Time: Tuesday, Apr 29 2008 9:30 AM - 9:45 AM Session Title: RPE Cell Biology Session Number: 309 Abstract: #2438 Title: Oxidative Stress-Induced Apoptosis and Pro-Inflammatory Cox-2 Expression Are Down-Regulated by Resolvins in Retinal Pigment- Epithelial (arpe-19) Cells Organizing Section: Retinal Cell Biology Location: Floridian Ballroom A Date & Time: Thursday, May 1 2008 11:30 AM - 11:45 AM Session Title: Regulation of CNV in Animal Models Session Number: 529 Abstract: #5414 Title: Resolvin E1 or a Resolvin E1 Analog Inhibits Vascular Leakage in Experimental Choroidal Neovascularization (CNV) Organizing Section: Retinal Cell Biology Location: Floridian Ballroom A Date & Time: Thursday, May 1 2008 11:00 AM - 11:15 AM Session Title: Regulation of CNV in Animal Models Session Number: 529 Abstract: #5412 Title: Systemic Neuroprotectin D1 (NPD1) Is a Potent Inhibitor of Laser-Induced Choroidal Neovascularization Organizing Section: Retinal Cell Biology Location: Floridian Ballroom A Poster Presentations: Date & Time: Sunday, Apr 27 2008 8:30 AM - 10:15 AM. Session Title: Treating Dry Eye Disease Session Number: 106 Abstract: #121/A148 Title: The Resolvin E1 Analogs, RX-10065 and RX-10005 Improve Tear Production and Decrease Inflammation in a Mouse Dry Eye Model Organizing Section: Cornea Location: Exhibit Hall B/C Date & Time: Sunday, Apr 27 2008 8:30 AM - 10:15 AM. Session Title: Treating Dry Eye Disease Session Number: 106 Abstract: #122/A149 Title: Resolvins Protect Against Goblet Cell Loss and Reduce Corneal Epithelial Barrier Disruption in a Murine Model of KCS Organizing Section: Cornea Location: Exhibit Hall B/C Date & Time: Sunday, Apr 27 2008 8:30 AM - 10:15 AM Session Title: Treating Dry Eye Disease Session Number: 106 Abstract: #125/A152 Title: Resolvins Inhibit Hypertonicity-Induced Proinflammatory Cytokine Release by Suppressing Mapk Pathway Activation in Human Corneal Epithelial Cells Organizing Section: Cornea Location: Exhibit Hall B/C Date & Time: Tuesday, Apr 29 2008 11:15 AM - 1:00 PM Session Title: Drug Delivery II Session Number: 358 Abstract: #3179/D912 Title: Resolvin Analogs With Pharmacokinetic Properties Suitable for Topical Administration to Treat Ocular Diseases Organizing Section: Physiology/Pharmacology Location: Exhibit Hall B/C Date & Time: Tuesday, Apr 29 2008 3:00 PM - 4:45 PM Session Title: Corneal Epithelium: Culture/Wound Healing/Development Session Number: 384 Abstract: #3396/A250 Title: Resolvins Stimulate Human Corneal Epithelial Cell Migration Organizing Section: Cornea/Anatomy Pathology Location: Exhibit Hall B/C
Resolvins are a recently discovered family of naturally-occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases. In particular, resolvins act to protect healthy tissue during an immuno-inflammatory response to infection, injury or other environmental challenge, and then act to resolve inflammation and promote healing after the environmental insult has passed. Resolvins have shown highly potent efficacy in pre-clinical models of asthma, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, dry eye and retinal disease, among others.
Resolvins are potential drug candidates to treat a broad range of acute and chronic diseases caused by a failure to resolve the inflammatory response and restore immune homeostasis. Such diseases include auto-immune diseases (like Crohn's disease, psoriasis and rheumatoid arthritis), allergic diseases (like asthma) and chronic inflammatory disease (like atherosclerosis, degenerative retinal diseases, chronic dry eye and Alzheimer's disease). Resolvins offer an entirely novel biological approach to treating significant inflammatory diseases, with a decreased potential for immuno-suppression.
About Resolvyx Pharmaceuticals
Resolvyx Pharmaceuticals is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of resolvins, a novel class of therapies to treat inflammatory diseases and their complications. Resolvyx's drug R&D programs are focused on characterizing and developing resolvin-based compounds. With its experienced management team, world-class scientists and leading investors, Resolvyx is well-positioned to capitalize on its extensive portfolio of more than 55 patents and applications. The company's headquarters are in Bedford, Massachusetts.
For additional information, please visit www.resolvyx.com.
Yates Public Relations
Kathryn Morris, 845-635-9828
Posted: April 2008